Ironwood Pharmaceuticals (IRWD) Liabilities and Shareholders Equity (2016 - 2025)
Ironwood Pharmaceuticals (IRWD) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $396.9 million as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 13.11% to $396.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, down 7.1% year-over-year, with the annual reading at $396.9 million for FY2025, 13.11% up from the prior year.
- Liabilities and Shareholders Equity hit $396.9 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $396.1 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q1 2023 to a low of $327.2 million in Q1 2025.
- Historically, Liabilities and Shareholders Equity has averaged $690.2 million across 5 years, with a median of $561.7 million in 2021.
- Biggest five-year swings in Liabilities and Shareholders Equity: soared 127.09% in 2021 and later plummeted 62.02% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then dropped by 2.34% to $1.1 billion in 2022, then tumbled by 57.2% to $471.1 million in 2023, then dropped by 25.51% to $350.9 million in 2024, then rose by 13.11% to $396.9 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for IRWD at $396.9 million in Q4 2025, $396.1 million in Q3 2025, and $342.9 million in Q2 2025.